29 March 2022 - Minneapolis, United States - Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that it has entered into a development agreement with MIPM Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external defibrillator.
News | 04-29-2022
IMRICOR announces development agreement with MIPM
Given the challenge of ablating complex arrhythmias such as VT in iCMR, an external defibrillator is required that can be deployed during the procedure while the patient is in iCMR.
Nick Twohy, Vice President of Marketing and Business Development at Imricor, said: ‘We are delighted to be working with a world leader in MRI-compatible devices. MIPM's defibrillator and technology are critical to the success of performing complex iCMR ablations.’
Under the terms of the agreement, Imricor and MIPM will collaborate on product development and clinical trials, including Imricor's upcoming trial to expand indications to include complex ablation procedures.
Andreas Klement, Vice President, stated: ‘The MIPM is very pleased about the cooperation with Imricor and expects a long-term and fruitful collaboration in this innovative field of electrophysiological investigations and ablation procedures in the MR environment.’